Atai Life Sciences (ATAI) Competitors $1.50 +0.03 (+2.04%) Closing price 04:00 PM EasternExtended Trading$1.48 -0.02 (-1.07%) As of 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATAI vs. AMPH, SNDX, BGM, AUPH, ETNB, WVE, ELVN, ZYME, XFOR, and PHVSShould you be buying Atai Life Sciences stock or one of its competitors? The main competitors of Atai Life Sciences include Amphastar Pharmaceuticals (AMPH), Syndax Pharmaceuticals (SNDX), Qilian International Holding Group (BGM), Aurinia Pharmaceuticals (AUPH), 89bio (ETNB), Wave Life Sciences (WVE), Enliven Therapeutics (ELVN), Zymeworks (ZYME), X4 Pharmaceuticals (XFOR), and Pharvaris (PHVS). These companies are all part of the "pharmaceutical products" industry. Atai Life Sciences vs. Amphastar Pharmaceuticals Syndax Pharmaceuticals Qilian International Holding Group Aurinia Pharmaceuticals 89bio Wave Life Sciences Enliven Therapeutics Zymeworks X4 Pharmaceuticals Pharvaris Amphastar Pharmaceuticals (NASDAQ:AMPH) and Atai Life Sciences (NASDAQ:ATAI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, community ranking, earnings, profitability, dividends, media sentiment and analyst recommendations. Do analysts prefer AMPH or ATAI? Amphastar Pharmaceuticals currently has a consensus target price of $43.50, indicating a potential upside of 82.16%. Atai Life Sciences has a consensus target price of $10.50, indicating a potential upside of 614.29%. Given Atai Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Atai Life Sciences is more favorable than Amphastar Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amphastar Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Atai Life Sciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is AMPH or ATAI more profitable? Amphastar Pharmaceuticals has a net margin of 21.80% compared to Atai Life Sciences' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 26.44% beat Atai Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Amphastar Pharmaceuticals21.80% 26.44% 11.89% Atai Life Sciences N/A -65.75%-52.71% Does the MarketBeat Community favor AMPH or ATAI? Amphastar Pharmaceuticals received 58 more outperform votes than Atai Life Sciences when rated by MarketBeat users. However, 66.53% of users gave Atai Life Sciences an outperform vote while only 65.88% of users gave Amphastar Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAmphastar PharmaceuticalsOutperform Votes39265.88% Underperform Votes20334.12% Atai Life SciencesOutperform Votes33466.53% Underperform Votes16833.47% Does the media favor AMPH or ATAI? In the previous week, Amphastar Pharmaceuticals had 4 more articles in the media than Atai Life Sciences. MarketBeat recorded 5 mentions for Amphastar Pharmaceuticals and 1 mentions for Atai Life Sciences. Atai Life Sciences' average media sentiment score of 1.89 beat Amphastar Pharmaceuticals' score of 1.26 indicating that Atai Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment Amphastar Pharmaceuticals Positive Atai Life Sciences Very Positive Which has better valuation & earnings, AMPH or ATAI? Amphastar Pharmaceuticals has higher revenue and earnings than Atai Life Sciences. Atai Life Sciences is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmphastar Pharmaceuticals$731.97M1.55$137.54M$3.067.80Atai Life Sciences$308K953.57-$40.22M-$0.93-1.58 Do insiders and institutionals hold more shares of AMPH or ATAI? 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 28.4% of Atai Life Sciences shares are owned by institutional investors. 27.1% of Amphastar Pharmaceuticals shares are owned by insiders. Comparatively, 31.2% of Atai Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, AMPH or ATAI? Amphastar Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Atai Life Sciences has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500. SummaryAmphastar Pharmaceuticals beats Atai Life Sciences on 10 of the 18 factors compared between the two stocks. Get Atai Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ATAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATAI vs. The Competition Export to ExcelMetricAtai Life SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$299.69M$6.85B$5.54B$7.93BDividend YieldN/A2.96%5.09%4.23%P/E Ratio-1.817.3222.5818.55Price / Sales953.57241.43401.13103.29Price / CashN/A65.8538.1834.62Price / Book1.006.486.774.25Net Income-$40.22M$143.41M$3.22B$248.18M7 Day Performance0.68%1.92%1.10%0.91%1 Month Performance-0.68%4.29%2.49%2.59%1 Year Performance-30.99%-3.87%15.76%4.02% Atai Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATAIAtai Life Sciences2.6885 of 5 stars$1.50+2.0%$10.50+600.0%-28.3%$299.69M$308,000.00-1.8580AMPHAmphastar Pharmaceuticals4.5152 of 5 stars$24.25+0.2%$43.50+79.4%-43.3%$1.15B$731.97M8.081,620Upcoming EarningsPositive NewsGap UpSNDXSyndax Pharmaceuticals3.6655 of 5 stars$13.39+0.4%$36.20+170.4%-37.1%$1.15B$23.68M-3.68110Upcoming EarningsPositive NewsBGMQilian International Holding GroupN/A$11.35+2.3%N/AN/A$1.10B$25.10M0.00298News CoverageAUPHAurinia Pharmaceuticals2.6584 of 5 stars$8.05-1.7%$11.50+42.9%+57.7%$1.10B$235.13M-53.63300Positive NewsETNB89bio2.9922 of 5 stars$7.28+4.8%$27.25+274.6%-7.1%$1.06BN/A-2.5040Earnings ReportUpcoming EarningsAnalyst UpgradeAnalyst RevisionNews CoveragePositive NewsGap UpWVEWave Life Sciences4.2426 of 5 stars$6.77+0.5%$22.18+227.9%+40.0%$1.04B$108.30M-6.09240Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageELVNEnliven Therapeutics2.3031 of 5 stars$18.51+1.7%$40.33+117.9%+9.7%$910.49MN/A-9.7850News CoveragePositive NewsZYMEZymeworks2.7588 of 5 stars$12.88+2.5%$21.00+63.0%+47.0%$896.78M$76.30M-8.59460Upcoming EarningsAnalyst RevisionNews CoveragePositive NewsXFORX4 Pharmaceuticals3.9907 of 5 stars$5.13-10.0%$85.00+1,556.9%-88.7%$890.89M$2.56M-56.9980Earnings ReportAnalyst ForecastStock SplitNews CoverageGap UpHigh Trading VolumePHVSPharvaris2.0349 of 5 stars$16.96+0.7%$42.67+151.5%-27.4%$887.05MN/A-6.0630Analyst ForecastAnalyst RevisionNews CoveragePositive News Related Companies and Tools Related Companies AMPH Competitors SNDX Competitors BGM Competitors AUPH Competitors ETNB Competitors WVE Competitors ELVN Competitors ZYME Competitors XFOR Competitors PHVS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATAI) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atai Life Sciences Please log in to your account or sign up in order to add this asset to your watchlist. Share Atai Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ATAI Stock Free ATAI Stock Alerts